Monkeypox numbers are on the run.
In fact, according to StatNews.com, “The current outbreak, first detected in mid-May, has now spread to at least 49 countries, with more than 4,700 monkeypox cases reported so far. In the United States, 306 cases have been detected in 27 states and the District of Columbia.”
According to The White House, it’s far less transmissible than COVID. However, it is spreading in the U.S. and globally, and “requires a comprehensive response from federal, state, local, and international governments and communities.”
As a result, “The Biden-Harris Administration announced the first phase of its national monkeypox vaccine strategy, a critical part of its monkeypox outbreak response. The vaccine strategy will help immediately address the spread of the virus by providing vaccines across the country to individuals at high risk. This phase of the strategy aims to rapidly deploy vaccines in the most affected communities and mitigate the spread of the disease.”
To help, the U.S. will distribute 56,000 doses of Jynneos, which is made by Bavarian Nordic (BVNRY). The U.S. expects to receive another 750,000 doses in weeks, and 500,000 more by the time fall is here.
Another monkeypox stock to keep an eye on is Emergent BioSolutions (EBS). Be careful with EBS though. While the U.S. will allow states to order the company’s ACAM2000, which has been approved to prevent smallpox, Barron’s notes that it does have “significant side effects.”
It’s just something to keep in mind if you’re looking for monkeypox trade ideas.